Belgium will not reimburse lecanemab, a treatment for people with early Alzheimer’s disease, after the Commission for the Reimbursement of Medicines (CTG) issued a negative recommendation. Health and Social Affairs Minister Frank Vandenbroucke announced that he would follow the committee’s advice.
According to a statement released by the minister’s office on 5 June, the CTG concluded that the treatment “did not live up to its promises”. The committee found that lecanemab’s effect on slowing cognitive and functional decline was not sufficiently convincing. The CTG also highlighted the lack of data on long-term outcomes and mortality.
https://vandenbroucke.belgium.be/fr/actualites/la-crm-rend-un-avis-defavorable-sur-leqembi-le-ministre-vandenbroucke-suit-cet-avis
